ES2109554T3 - Agentes de reversion de la resistencia a multiples farmacos. - Google Patents

Agentes de reversion de la resistencia a multiples farmacos.

Info

Publication number
ES2109554T3
ES2109554T3 ES94110067T ES94110067T ES2109554T3 ES 2109554 T3 ES2109554 T3 ES 2109554T3 ES 94110067 T ES94110067 T ES 94110067T ES 94110067 T ES94110067 T ES 94110067T ES 2109554 T3 ES2109554 T3 ES 2109554T3
Authority
ES
Spain
Prior art keywords
pharmaces
resistance
reversion agents
compounds
chemotherapeutic agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94110067T
Other languages
English (en)
Inventor
Dennis Powell
Rolf Paul
William A Hallett
Dan M Berger
Minu D Dutia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of ES2109554T3 publication Critical patent/ES2109554T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/01—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and halogen atoms, or nitro or nitroso groups bound to the same carbon skeleton
    • C07C323/02—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and halogen atoms, or nitro or nitroso groups bound to the same carbon skeleton having sulfur atoms of thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/07—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and halogen atoms, or nitro or nitroso groups bound to the same carbon skeleton having sulfur atoms of thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/16—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/56—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Gyroscopes (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Permanent Magnet Type Synchronous Machine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

SE PRESENTAN COMPUESTOS CON UNA FORMULA GENERAL, DONDE SE DESCRIBEN R1, R2, R3, R4 Y R5. A ES UN (C2-C12)ALQUILO RECTO O RAMIFICADO O UNA PORCION DE FENIL Y B ES UNA PORCION CON LA FORMULA QUE SE ESPECIFICA. LOS COMPUESTOS SON EFECTIVOS PARA POTENCIAR LA ACTIVIDAD DE AGENTES QUIMIOTERAPEUTICOS ANTICANCERIGENOS AL INCREMENTAR LA SENSIBILIDAD DE CELULAS RESISTENTES A MULTIPLES DROGAS RESPECTO A TALES AGENTES QUIMIOTERAPEUTICOS.
ES94110067T 1993-07-16 1994-06-29 Agentes de reversion de la resistencia a multiples farmacos. Expired - Lifetime ES2109554T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/092,653 US5387685A (en) 1993-07-16 1993-07-16 MDR reversal agents

Publications (1)

Publication Number Publication Date
ES2109554T3 true ES2109554T3 (es) 1998-01-16

Family

ID=22234360

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94110067T Expired - Lifetime ES2109554T3 (es) 1993-07-16 1994-06-29 Agentes de reversion de la resistencia a multiples farmacos.

Country Status (28)

Country Link
US (4) US5387685A (es)
EP (1) EP0634401B1 (es)
JP (1) JPH07179422A (es)
KR (1) KR950003274A (es)
CN (1) CN1049891C (es)
AT (1) ATE156816T1 (es)
AU (1) AU691495B2 (es)
CA (1) CA2128139A1 (es)
CZ (1) CZ157294A3 (es)
DE (1) DE69404917T2 (es)
DK (1) DK0634401T3 (es)
EC (1) ECSP941118A (es)
ES (1) ES2109554T3 (es)
FI (1) FI943392L (es)
GR (1) GR3025105T3 (es)
HU (1) HU218478B (es)
IL (1) IL110294A0 (es)
NO (1) NO303173B1 (es)
NZ (1) NZ264013A (es)
PE (1) PE4495A1 (es)
PH (1) PH30780A (es)
PL (1) PL304320A1 (es)
RU (1) RU94026288A (es)
SG (1) SG47662A1 (es)
SI (1) SI0634401T1 (es)
SK (1) SK79594A3 (es)
TW (1) TW302360B (es)
ZA (1) ZA945211B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150398A (en) * 1991-05-08 2000-11-21 The United States Of America As Represented By The Department Of Health And Human Services Methods for the treatment of cancer
JPH10505348A (ja) 1994-08-31 1998-05-26 イーライ・リリー・アンド・カンパニー 耐性腫瘍の同定および治療方法
US5726184A (en) * 1995-05-19 1998-03-10 Vertex Pharmaceuticals Incorporated Tetralin compounds with improved MDR activity
US6395770B1 (en) * 1995-10-26 2002-05-28 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
US6245805B1 (en) 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US5968972A (en) * 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
US6162616A (en) * 1997-04-16 2000-12-19 Millennium Pharmaceuticals, Inc. Multidrug resistance-associated polypeptide
JP2942824B1 (ja) * 1998-03-13 1999-08-30 工業技術院長 シリルチオアルケン化合物及びその製造方法
US6372775B1 (en) * 1998-05-27 2002-04-16 American Cyanamid Company Reversal of multidrug resistance in human colon carcinoma cells
CA2408913A1 (en) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
US6376514B1 (en) * 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
ATE441417T1 (de) 2002-12-20 2009-09-15 Glaxo Group Ltd Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
US7704993B2 (en) * 2003-06-17 2010-04-27 Arena Pharmaceuticals, Inc. Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
SI2332921T1 (sl) 2003-06-17 2016-06-30 Arena Pharmaceuticals, Inc. 8-kloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzazapin hidroklorid
WO2005046578A2 (en) 2003-09-23 2005-05-26 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
AU2004276238B2 (en) 2003-09-23 2010-10-28 Merck Sharp & Dohme Corp. Isoquinolinone potassium channel inhibitors
WO2005042490A1 (en) * 2003-10-22 2005-05-12 Arena Pharmaceuticals, Inc. Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
WO2005042491A1 (en) * 2003-10-22 2005-05-12 Arena Pharmaceuticals, Inc. Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
CA2589988C (en) 2004-12-21 2017-02-14 Arena Pharmaceuticals, Inc. Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride
PT1833473E (pt) 2004-12-23 2009-12-17 Arena Pharm Inc Composições de modulador de receptor 5ht2c e métodos de utilização
EP2518053A1 (en) 2006-04-03 2012-10-31 Arena Pharmaceuticals, Inc. Process for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine
EP2099743B1 (en) * 2006-12-05 2014-08-27 Arena Pharmaceuticals, Inc. Processes for preparing (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates thereof
JP5491421B2 (ja) * 2008-03-04 2014-05-14 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ｈｔ２ｃアゴニストである（ｒ）−８−クロロ−１−メチル−２，３，４，５−テトラヒドロ−１ｈ−３−ベンゾアゼピンに関連する中間体の調製のためのプロセス
CN102648170A (zh) 2009-06-18 2012-08-22 艾尼纳制药公司 制备5-ht2c受体激动剂的方法
WO2011153206A1 (en) 2010-06-02 2011-12-08 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-ht2c receptor agonists
CN103347523A (zh) 2010-09-01 2013-10-09 艾尼纳制药公司 向具有肾损伤的个体给药氯卡色林
WO2012030957A2 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Non-hygroscopic salts of 5-ht2c agonists
KR20180118801A (ko) 2010-09-01 2018-10-31 에자이 알앤드디 매니지먼트 가부시키가이샤 체중 관리에 유용한 5-ｈｔ2ｃ 작동제의 변형-방출 투여 형태
MX2013002422A (es) 2010-09-01 2013-05-17 Arena Pharm Inc Sales de lorcaserina con acidos opticamente activos.
WO2014058441A1 (en) 2012-10-09 2014-04-17 Arena Pharmaceuticals, Inc. Method of weight management
CN105263899B (zh) * 2013-01-21 2017-11-14 国立大学法人大阪大学 苯氧基烷基胺化合物
CA2938626A1 (en) 2013-07-26 2015-01-29 John Rothman Compositions to improve the therapeutic benefit of bisantrene
WO2019075287A1 (en) 2017-10-13 2019-04-18 Bayer Healthcare Llc KIOSK OF DISTRIBUTION OF FOOT CARE PRODUCTS
CN110240554B (zh) * 2019-06-27 2021-02-23 上海大学 α-硫醚芳基乙腈类化合物及其合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2969362A (en) * 1959-08-11 1961-01-24 Searle & Co 2-[alpha-(haloalkyl) benzylthio] imidazolines and tetrahydropyrimidines corresponding
FR2588258B1 (fr) * 1985-10-04 1989-12-15 Adir Nouveaux derives d'amino-5 valeronitrile, leurs procedes de preparation et les compositions pharmaceutiques les renfermant
US4833162A (en) * 1988-02-03 1989-05-23 American Cyanamid Company Substituted benzeneacetonitriles and their use as calcium channel blockers
DK0409406T3 (da) * 1989-06-19 1994-02-07 Wellcome Found Arylsubstituerede aminderivater, der er anvendelige ved cancerterapi
HUT68856A (en) * 1991-01-11 1995-08-28 Glaxo Lab Sa Acridine derivatives, pharmaceutical compositions comprising the same compouds as effective substances and a process for producing the compounds and the pharmaceutical compositions
FR2673627B1 (fr) * 1991-03-07 1993-05-07 Adir Triazines et pyrimidines trisubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant.
DE69310367T2 (de) * 1992-07-10 1997-08-14 Glaxo Lab Sa Anilide-derivate

Also Published As

Publication number Publication date
DK0634401T3 (da) 1998-03-16
SK79594A3 (en) 1995-04-12
SG47662A1 (en) 1998-04-17
US5639887A (en) 1997-06-17
SI0634401T1 (en) 1998-02-28
IL110294A0 (en) 1994-10-21
NO942673D0 (no) 1994-07-15
CN1049891C (zh) 2000-03-01
RU94026288A (ru) 1996-05-27
FI943392A0 (fi) 1994-07-15
ECSP941118A (es) 1995-02-27
NO303173B1 (no) 1998-06-08
HU9402111D0 (en) 1994-09-28
EP0634401A1 (en) 1995-01-18
EP0634401B1 (en) 1997-08-13
PE4495A1 (es) 1995-03-13
AU691495B2 (en) 1998-05-21
TW302360B (es) 1997-04-11
ZA945211B (en) 1995-02-28
FI943392A7 (fi) 1995-01-17
US5561141A (en) 1996-10-01
KR950003274A (ko) 1995-02-16
GR3025105T3 (en) 1998-01-30
NO942673L (no) 1995-01-17
JPH07179422A (ja) 1995-07-18
NZ264013A (en) 1995-11-27
AU6750194A (en) 1995-01-27
US5550149A (en) 1996-08-27
CZ157294A3 (en) 1995-05-17
HUT71412A (en) 1995-11-28
HU218478B (hu) 2000-09-28
DE69404917D1 (de) 1997-09-18
US5387685A (en) 1995-02-07
CN1114650A (zh) 1996-01-10
CA2128139A1 (en) 1995-01-17
ATE156816T1 (de) 1997-08-15
DE69404917T2 (de) 1998-01-15
FI943392L (fi) 1995-01-17
PH30780A (en) 1997-10-17
PL304320A1 (en) 1995-01-23

Similar Documents

Publication Publication Date Title
ES2109554T3 (es) Agentes de reversion de la resistencia a multiples farmacos.
ES2017611T3 (es) Tiazoles sustituidos y su uso como fungicidas.
MX9203122A (es) Compuestos analogos de distamicina a y composiciones farmaceuticas que los contienen.
FI894352A0 (fi) Optiskt icke-lineaera aktiva organiska foereningar och elektrooptiska apparater innehaollande dessa.
TR199903277T2 (xx) Benzimidazol t�revleri.
DE69728544D1 (de) Totalsynthese von acylfulvenen mit antitumorwirkung
SE8503415D0 (sv) Novel isoindolinyl-alkyl-piperazines
DK288686A (da) Farmaceutiske praeparater
ES2134732B1 (es) "mezclas estabilizantes".
SE8500107D0 (sv) Neue 8alfa-acylaminoergoline
FI854603A0 (fi) Foerfarande och mellanprodukter foer framstaellning av 5-alkyl-1-fenyl-2-piperazino-alkylpyrazolin-3-on -foereningar.
ES8801621A1 (es) Un procedimiento para preparar derivados arilicos de dienamidas
ITMI931012A1 (it) Composti spiro-piranici dotati di caratteristiche fotocromatiche
ES2109244T3 (es) Medicamentos que contienen compuestos de 3,7-diazabiciclo(3,3,1)nonano.
ES2062170T3 (es) Composiciones de tinta con base agua.
ES2072304T3 (es) Pirazolinas n-sulfeniladas y n-aciladas.
CA2027542A1 (en) Uv-absorbing cyclic enaminoketones
KR890010125A (ko) I 이상의 트리아졸로피리미돈 라디칼을 함유하는 신규 이소인돌린안료
MX9203518A (es) 9-amino-2-fenilbiciclo [3.3.1] nonanos y 9-amino-2-fenilbiciclo [3.3.1] non-2-enos y drogas que los contienen.
ES2012766B3 (es) Derivados de imino-3 piridazina, procedimiento de obtencion y formas farmaceuticas que las contienen.
ATE209226T1 (de) Polyglycidylether von sekundären alkoholen
TH18904A (th) สารผสมที่มีสารประกอบเบนโซไดฟิวราโนนและวิธีทำวัสดุชนิดไม่ชอบน้ำให้มีสีโดยการใช้สารผสมนี้
TH7623A (th) การปรับปรุงภายในหรือที่เกี่ยวข้องกับสารอินทรีย์
SE8501168D0 (sv) 2,5-metanobenso(g)kinolin-3-karboxylater till anvendning som kemiska intermedierer
TH20772A (th) อนุพันธ์(3-(4-เฟนิลเพทเพทอราซิน-1-อิล) โพรพิลอมิโน)-ไพริดีน,ไพริมิดีนและเบนซีน การใช้สารเห่านี้เป็นยาและการเตรียมสารเหล่านี้

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 634401

Country of ref document: ES